Hospital Services – Coverage of Gene Therapies for Sickle Cell Disease LAC 50:V.120
Continues the July 1, 2025 Emergency Rule which adopted cell and gene therapy model that provides additional supplemental and federal rebates for gene therapies for sickle cell disease.